血清CYFRA21-1、CEA和NSE联合检测对肺癌的诊断价值

Diagnostic value of combined detection of CYFRA21-1,CEA and NSE in patients with lung cancer

目的探讨肿瘤标志物CYFRA21-1、CEA和NSE单项和联合检测对肺癌诊断价值。方法采用放射免疫法检测65例肺癌患者和50例肺部良性疾病患者血清三项标志物水平,并以38名健康志愿者为正常对照组。结果肺癌患者CYFRA21-1、CEA和NSE血清水平高于肺良性疾病患者和正常对照组,差异有统计学意义(P<0.01),肺部良性疾病患者和健康人比较差异无统计学意义。三项标志物在肺癌不同病理类型中,鳞癌CYFRA21-1水平均高于腺癌和小细胞癌,小细胞癌NSE水平高于鳞癌和腺癌(P<0.01)。三项标志物联合检测的灵敏度为91.6%,明显高于单项检测灵敏度。结论CYFRA21-1、CEA和NSE联合检测可明显提高肺癌的阳性检出率,联合检测对鉴别肺癌与肺部良性疾病、肺癌不同病理类型患者有一定的诊断价值。

Objective To explore the value of combined detection of CYFRA21-1, CEA and NSE in diagnosis of lung cancer. Methods The serum levels of CYFRA21-1,CEA and NSE were determined by radioimmunoassay in 65 patients with lung cancer, 50 patients with benign pulmonary disease and 38 normal controls. Results The levels of serum CYFRA21-1, CEA and NSE in lung cancer patients were significantly higher than that in patients with benign pulmonary disease and controls（P〈 0.01）. The CYFRA21-1, NSE had significant difference in different pathological types of lung cancer. The sensitivity of combined detection was significantly higher than that of single detection. Conclusion The results indicate that the combined detection of CYFRA21-1, CEA and NSE can increase the diagnostic sensitivity of lung cancer, and distinguish the different pathological types of lung cancer.